Skip to main content
. 2009 Sep 29;1:13–21. doi: 10.2147/hiv.s4842

Figure 2.

Figure 2

Percentage of patients in whom pretreatment isolates that were susceptible to protease inhibitors remained so after failure of darunavir/ritanovir (DRV/RTV) or lopinavir/ritanovir (LPV/RTV) in the TITAN trial. Drawn from data of de Meyer.35